Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb trial in ulcerative colitis (UC) and Crohn’s disease (CD). In the RELIEVE UCCD long-term extension (LTE) study (NCT05668013), pat... See more
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Patients in cohort three of the Phase III BREAKWATER trial (NCT04607421) received a combination o... See more
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in patients with early-stage (II-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). In the LIBRE... See more
Breye Therapeutics’ oral small molecule for non-proliferative diabetic retinopathy (NPDR) has demonstrated safety and early signs of improving disease activity in an early-stage trial. In the Phase Ib study, Breye’s lead candidate, danegaptide, demonstrat... See more
Priovant advances CS drug to Phase III after 100% response in Phase II Abigail Beaney Mon, February 9, 2026 at 6:30 PM UTC Add Yahoo Health on Google Priovant Therapeutics will advance the drug to a Phase III trial in 2026. Image credit: 3rdtimeluckystudi... See more
